<DOC>
	<DOCNO>NCT01555515</DOCNO>
	<brief_summary>In End Stage Renal Disease ( ESRD ) patient need Erythropoietin ( epo ) hormone get small implant skin use skin , implant treat laboratory program secrete Epo . The implant secrete patient epo minimize need injection period 6 month .</brief_summary>
	<brief_title>Epodure Therapy Anemia End Stage Renal Disease Dialysis With Epodure Skin Implant</brief_title>
	<detailed_description>This Phase I-II , open-label , single-center , uncontrolled , tailor dose study . The trial conduct Israel Tel Aviv Sourasky Medical Center . Subjects undergo similar study procedure evaluation ; however patient receive individually target dose EPO deliver via EPODURE Biopumps . The targeted dose may vary 20IU/kg/d 65IU/kg/d base patient 's weight , historical average EPO amount administer historical Hb level include least 3 month prior inclusion study . The objective maintaining Hb level within target range 10-12 g/dl .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . 1 . Adult male female subject 18 75 year age time screen visit . 2 . Subject diagnosed Anemia due Chronic Renal Failure CKD stage 5 dialysis treatment least 3 month . Hb &lt; 12g/dL 2 consecutive measure 3 . Kt/V &gt; 1 4 . INR high 1.2 5 . Subjects clinically stable . 6 . Serum albumin &gt; 3.5 7 . Subjects adequate iron store ( transferrin saturation &gt; 20.0 % and/or ferritin &gt; 100 ng/ml ) . 8 . Signed write informed consent participate study . 1 . Uncontrolled hypertension ( define diastolic blood pressure &gt; 110 mmHg systolic blood pressure &gt; 180 mmHg screening ) . 2 . Subjects receive oral anticoagulation treatment ( warfarin ) 3 . Subjects receive Acetyl Salicylic Acid [ ( ASA ) , aspirin ] 325 mg/day patient receive ASA treatment 100mg/d 325 mg/d discontinue 1 week prior EPODURE procedure 4 . Patients currently receive injection longacting ESA 's ( Aranesp , Mircera , etc . ) 5 . Congestive heart failure ( New York Heart Association functional class III IV ) . 6 . Grand mal seizure within 2 year screen visit . 7 . Clinical evidence severe hyperparathyroidism define PTH level &gt; 10 time upper normal limit . 8 . Major surgery within 12 week screen visit . 9 . Systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia ) . 10 . Current systemic infection , active inflammatory disease , malignancy treatment . 11 . Subjects know test positive time past antibody erythropoietic protein . 12 . Subject history malignancy within past 2 year prior screen visit , exception basal cell carcinoma . 13 . Subjects concurrent severe and/or uncontrolled medical condition could compromise participation study ( i.e . active infection , uncontrolled diabetes , uncontrolled hypertension , congestive cardiac failure , unstable angina , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month , uncompensated cirrhosis , active upper GI tract ulceration ) . 14 . Subject currently enrol , yet complete period least 30 day since end investigational device drug trial ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>